Expectation alone can ease pain, and the ritual of being treated has a dose of its own. That is why someone feeling better after a treatment tells you almost nothing about whether the treatment worked.
The placebo effect is not a curiosity here: it is the reason a controlled trial earns weight and a testimonial does not.
What Expectation Actually Does
Expectation, conditioning and the ritual of care produce real physical responses - the body's own opioids and dopamine, not an invented symptom. That mechanism is written once, on the placebo effect. What matters here is the consequence for evidence: those responses happen whether or not a treatment does anything.
It Moves Symptoms, Not Disease
Placebos act powerfully on self-reported symptoms, above all pain, and much less on the objective course of disease.
Two large syntheses, Hrobjartsson 2001 and 2010, gathered every trial pitting a placebo against no treatment. In the 2010 review of 202 trials, placebo modestly eased patient-reported symptoms, clearest for pain. In the earlier 114-trial review, it did not move outcomes read from a scan or a test.
A placebo can make a person hurt less. It does not shrink a tumor, mend a fracture, or clear an infection. Treating a serious disease with belief in place of effective care is where the harm lies: someone delaying treatment for a condition a placebo was never going to touch.
The claim that belief cures serious disease takes a real, measured effect and pushes it beyond what any trial has shown.
The Research & Studies
Everything here is based on the research we have collected and checked, sorted into groups and ordered with the strongest evidence first. Click any claim to open the studies behind it.
How it works
Naloxone reverses placebo pain relief, so the body's own opioids do the work
People who got real pain relief from a placebo after dental surgery lost that relief when given a drug that blocks opioids. The placebo relief was running on the body's own opioids, not on imagination.
Levine, Gordon and Fields studied pain following extraction of impacted third molars. Patients who responded to a placebo with reduced pain lost that analgesia when given naloxone, an opioid antagonist, whereas naloxone had less effect where placebo had not produced relief. The reversal established that at least one major route of placebo analgesia is the release of endogenous opioids, giving the placebo effect a concrete neurochemical mechanism. Later imaging and pharmacological work has repeatedly confirmed opioid involvement in expectation-driven analgesia. Sex distribution of the dental-surgery sample was not reported in a way that supports a breakdown.
The study · 1
Levine, Gordon & Fields, The mechanism of placebo analgesia · Lancet 1978;2(8091):654-657
Placebo eases self-reported symptoms, mainly pain, across 202 trials
When researchers pooled every trial that pitted a placebo against getting nothing, the placebo made people feel modestly better on things they report themselves, above all pain. It did not change outcomes measured by a scan or a test.
The 2010 Cochrane review by Hrobjartsson and Gotzsche pooled 202 randomized trials in which one arm received a placebo and another received no treatment. Placebo showed a modest overall effect on continuous, patient-reported outcomes, most reliably pain, with the size varying widely by condition and trial quality, and little to no effect on binary outcomes or objective measures. Effects were larger where patients were informed the intervention was intended to strengthen the response and where the outcome was assessed by the patient, not an instrument. The authors concluded placebo can influence patient-reported outcomes, especially pain and nausea, but the evidence does not support a general clinical placebo effect on the course of disease.
The study · 1
Hrobjartsson & Gotzsche, Placebo interventions for all clinical conditions · Cochrane Database Syst Rev 2010;(1):CD003974
Placebo does not change objectively measured disease across 114 trials
Pooling 114 trials of placebo versus no treatment, the placebo did not change outcomes measured objectively, like lab values or physical findings. Whatever effect there was showed up only in symptoms people rated themselves, mainly pain.
The 2001 New England Journal of Medicine analysis by Hrobjartsson and Gotzsche, Is the placebo powerless?, compared placebo against no-treatment arms in 114 randomized trials. It found no statistically significant effect of placebo on binary outcomes and no important effect on objective continuous outcomes, with a possible small effect limited to continuous subjective outcomes, particularly pain. The finding directly counters the popular idea of a broad, disease-altering placebo effect: placebos do not shrink tumors, mend fractures or clear infections. Apparent recoveries after inert treatment are better explained by the natural course of illness and regression to the mean than by the placebo itself.
The study · 1
Hrobjartsson & Gotzsche, Is the placebo powerless? · N Engl J Med 2001;344(21):1594-1602
Expecting Parkinson's medication releases dopamine like a levodopa dose
When people with Parkinson's expected to get their medication, a brain scan showed their brains released dopamine, the chemical the disease lacks, just from the expectation. The placebo response had a visible chemical signature.
de la Fuente-Fernandez and colleagues used PET with raclopride, a tracer sensitive to dopamine release, in patients with Parkinson's disease. Expectation of receiving antiparkinsonian medication produced substantial release of endogenous dopamine in the dorsal and ventral striatum, comparable in magnitude to a therapeutic dose of levodopa or apomorphine. The result located the placebo response in Parkinson's within the reward and motor circuitry that the disease depletes, showing that expectation of benefit engages the same dopaminergic system the drug targets. It is a mechanistic imaging finding in a specific disease, not a claim that placebos slow Parkinson's progression.
The study · 1
de la Fuente-Fernandez et al., Expectation and dopamine release · Science 2001;293(5532):1164-1166
Placebo lowers activity in the brain's pain-processing regions on fMRI
Brain scans during placebo pain relief showed less activity in the regions that create the feeling of pain, and more activity in planning regions while people anticipated relief. Expectation was reshaping how the brain handled the pain signal.
Wager and colleagues used functional MRI during a placebo analgesia paradigm. Placebo reduced pain-related neural activity in regions including the thalamus, insula and anterior cingulate cortex during noxious stimulation, and increased activity in the prefrontal cortex during the anticipation of pain, consistent with a top-down expectation signal modulating pain processing. The study helped establish that placebo analgesia is not merely a change in reporting but a change in the central processing of the pain signal itself. It maps the expectancy mechanism, not testing a treatment.
The study · 1
Wager et al., Placebo-induced changes in FMRI in the anticipation and experience of pain · Science 2004;303(5661):1162-1167
A warm practitioner relationship lifted IBS relief from 28% to 62%
IBS patients were split into a waiting list, a brief sham treatment with little interaction, and the same sham given by a warm, attentive practitioner. Reported relief climbed with each step, from about 28% to 44% to 62%. The relationship itself raised how much relief people reported.
Kaptchuk and colleagues randomized 262 patients with irritable bowel syndrome to a waiting list, sham acupuncture with a limited practitioner interaction, or sham acupuncture delivered with an augmented, warm and attentive patient-practitioner relationship. Adequate relief at three weeks rose across the arms, approximately 28% on the waiting list, 44% with limited interaction, and 62% with the augmented relationship, a graded dose-response. The trial isolated the components of the placebo response and showed that the therapeutic ritual and the quality of the clinical relationship contribute an active, measurable effect over and above assessment and natural history. IBS cohorts skew female; the trial enrolled both sexes.
The study · 1
Kaptchuk et al., Components of placebo effect: randomised controlled trial in IBS · BMJ 2008;336(7651):999-1003
90% of statin muscle symptoms also appeared on an identical placebo
People who had quit statins over muscle symptoms took the statin, an identical dummy pill, and nothing, in random order over months. Ninety percent of the symptoms they logged on the statin also appeared on the dummy pill. The symptoms were real, but the drug was not causing most of them.
The SAMSON n-of-1 trial by Wood, Howard and colleagues enrolled 60 patients who had abandoned statin therapy because of adverse symptoms. Each undertook a randomized sequence of months on atorvastatin, months on identical placebo, and months with no tablet, recording daily symptom intensity. The symptom burden during placebo months was 90% of that during statin months, and there was no significant difference in symptom intensity between statin and placebo. This quantifies the nocebo component of statin intolerance: the symptoms are experienced, but most of the intensity is attributable to the act of taking a tablet and the expectation of harm, not to the drug. Both sexes were enrolled.
The studies · 2
Wood, Howard et al., N-of-1 trial of a statin, placebo, or no treatment to assess side effects (SAMSON) · N Engl J Med 2020;383(22):2182-2184
Colloca & Barsky, Placebo and nocebo effects · N Engl J Med 2020;382(6):554-561
Warning men about finasteride's sexual side effects raised them from 15% to 44%
Men taking finasteride for an enlarged prostate were either told about possible sexual side effects or not. Those who were warned reported these side effects about three times as often, roughly 44% versus 15%, on the identical medication. The warning itself raised the harm.
Mondaini and colleagues studied 120 men taking finasteride for benign prostatic enlargement, randomized as to whether they were informed that the drug could cause erectile dysfunction, reduced libido and ejaculation problems. Men counseled about these effects reported them at 43.6%, against 15.3% among men not informed, for the same medication and dose. The threefold difference is a clear nocebo effect: expectation of a specific harm substantially increased its reported occurrence. Because the trial enrolled only men, taking finasteride for a male condition, the size of any analogous effect in women is untested.
Who this may not transfer to:Measured only in men taking a drug for a male condition. The nocebo mechanism, expectation of harm increasing reported harm, is general and well documented in both sexes elsewhere, but the specific magnitude seen here has not been measured in women and should not be assumed to be the same.
The study · 1
Mondaini et al., Finasteride 5 mg and sexual side effects: how many are a nocebo phenomenon · J Sex Med 2007;4(6):1708-1712
Openly labeled placebo beat no treatment in IBS, 59% versus 35%
IBS patients who were openly told their pills were sugar pills, and that placebos can still help, reported more improvement than patients given nothing, about 59% against 35%. Knowing it was a placebo did not switch off the effect.
Kaptchuk and colleagues randomized 80 patients with irritable bowel syndrome to open-label placebo, pills openly described as inert together with an explanation that placebos can produce benefit through mind-body self-healing processes, or to no treatment. The open-label placebo group reported significantly higher rates of adequate relief and global improvement, on the order of 59% versus 35%, over three weeks. The result challenged the assumption that concealment is necessary for a placebo to work and opened the open-label placebo research line. It is a small, short trial in a symptom-defined condition, and open-label placebos have not been shown to affect objective disease.
The study · 1
Kaptchuk et al., Placebos without deception: a randomized controlled trial in IBS · PLoS One 2010;5(12):e15591
Pooled open-label placebo trials show a large benefit over no treatment (SMD about 0.88)
Pooling the handful of trials where people knowingly took a placebo, there was a sizeable benefit over getting nothing, in conditions like IBS, depression and back pain. The evidence base is still thin.
Charlesworth and colleagues systematically reviewed and meta-analyzed randomized trials of open-label placebo, placebos given with full disclosure, against no treatment. Across a small set of trials in conditions such as irritable bowel syndrome, depression, allergic rhinitis, chronic low back pain and ADHD, open-label placebo showed a large pooled effect (standardized mean difference about 0.88, 95% CI 0.62 to 1.14) on self-reported outcomes. The authors emphasized the small number of trials, modest sample sizes and heterogeneity, and that outcomes were subjective. The synthesis supports open-label placebo as a researchable effect while keeping it firmly at an emerging tier, and confined to symptoms, not objective disease.
The study · 1
Charlesworth et al., Effects of placebos without deception compared with no treatment · J Evid Based Med 2017;10(2):97-107
The Ritual Has a Dose
The size of the response tracks how the treatment is delivered, which is why "we gave it and they improved" is not a measurement. A trial enrolled 262 patients with irritable bowel syndrome and split them three ways: a waiting list; a brief sham with little interaction; and the same sham inside a warm, attentive, unhurried relationship. Adequate relief climbed step by step, from about 28% to 44% to 62%.
Nothing in the treatment changed between the second and third arms. Only the encounter did. Any comparison that does not hold that steady is measuring the encounter as much as the treatment. The mechanisms behind it, including open-label placebos, are covered on the placebo effect.
Expectation Runs Backwards Too
Expecting harm produces it, and it accounts for a large share of the side effects blamed on drugs - which is the same problem in the other direction: a harm reported after a treatment is not evidence the treatment caused it. The trial evidence for that, including SAMSON, sits with the placebo effect.
Why This Means We Trust Controlled Trials
The method follows from the biology. Expectation and the ritual of care can move a symptom on their own. So a person improving after a treatment tells you little about whether the treatment did the work. Three forces make a symptom improve no matter what you do:
- the placebo response itself,
- the natural course of an illness that was going to ease anyway,
- regression to the mean: people seek help when they feel worst, then naturally drift back toward their average.
A single before-and-after story blends all three at once. The only way to separate the treatment's own effect is to compare it against a placebo delivered inside the same ritual. Then expectation and natural history land on both sides and cancel. What is left is the specific effect, if any exists.
Because expectation moves symptoms, only a design that holds expectation steady can show what a treatment is worth. A result that clears a matched placebo earns weight; an uncontrolled story earns the least, the logic behind how we grade evidence. Expectation and calm work through the body's stress axis.
Common Questions
Is the placebo effect all in my head?
No. The changes are physical: your brain releases its own opioids. "In your head" wrongly suggests the symptom is invented. The real split is between what you feel (pain, nausea, fatigue) and what a scan or blood test measures, and a placebo works on the first only.
Can a placebo cure a disease or shrink a tumor?
No. A placebo changes how a symptom feels while the underlying disease runs its course, so it cannot clear an infection or reverse a growth. When a tumor seems to shrink or a long illness lifts after an inert treatment, the cause is the illness's own natural rise and fall.
Do placebos work if I know it is a placebo?
Sometimes, for conditions defined by how a person feels. In one trial, people with irritable bowel syndrome were openly handed pills labeled inert, with a short explanation that placebos can work through mind-body pathways. About 59% improved, against 35% of those given nothing. Telling the truth about the pill did not switch the effect off.
What is the nocebo effect?
Expecting harm can produce harm, the placebo effect running in reverse. Finasteride, a drug for an enlarged prostate, shows it plainly. Men explicitly warned of sexual side effects reported them about three times as often as men not warned: 44% against 15%, for the same medication. The warning, not only the chemical, shaped what they felt.
Why do controlled trials need a placebo group?
Because a no-treatment group is not enough on its own. A waiting list captures natural recovery and regression to the mean. It misses the expectation and ritual that a real pill or procedure carries. Only a matched placebo, given with the same ritual, isolates those, so the gap above it is the treatment's specific effect.
Explore Related
Other pages this one connects to, by the evidence they share, the outcomes they touch, and the ground they cover.
How this connects
All 11 sources on this page independently checked and cross-referenced.
Thomas Dehli, Founder & Editor, Sacred Lotus
Sacred Lotus has published Chinese medicine reference material since 2001. Integrative pages are held to the same standard as the herb and formula library: cite the source, grade the claim at its real strength, and say where the research has not looked. This page is educational and it is not medical advice. Last reviewed and updated August 10, 2026.